期刊
JOURNAL OF RHEUMATOLOGY
卷 48, 期 5, 页码 693-697出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.191209
关键词
arthritis; methotrexate; psoriatic arthritis; TNF receptors
类别
资金
- Corrona, LLC
- Celgene Corporation
The study found that apremilast monotherapy is an effective option for patients with oligoarticular PsA. Apremilast initiators experienced greater disease activity improvements at follow-up compared to MTX initiators.
Objective. Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA). Methods. Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included. Results. In total, 150 patients initiated rnonotherapy (aprernilast: n = 34; MTX: n = 15; bDMARD: n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators. Conclusion. Findings suggest aprernilast monotherapy is an effective option for patients with oligoarticular PsA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据